Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2022-02-15 / Leuk Lymphoma 2022 Jul;63(7):1733-1737Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891Research progress on dendritic cell vaccines in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):3Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-01-19 / Genes Immun 2022 02;23(1):1-11GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-01-07 / J Healthc Eng 2022;2022:2518847Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
/in Breast Cancer, Dendritic Cells, International Publications /von 2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-353A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
/in Dendritic Cells, International Publications, NSCLC /von 2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-01-01 / J Immunother Cancer 2022 Jan;10(1)Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
/in Dendritic Cells, International Publications, NSCLC /von 2021-12-24 / ESMO Open 2022 Feb;7(1):100334IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de